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Introduction
Giant cell arteritis (GCA) is a granulomatous disease that 
displays tissue tropism for large and medium arteries 
manifesting as aortitis and vasculitis of the second to ﬁ  fth 
branches of the aorta [1]. Granulomatous lesions are 
typically localized in the wall layers of the aﬀ  ected 
arteries; extra-vascular GCA is rare, and likely represents 
a distinct entity. Th   e arteritis is almost always combined 
with intense systemic inﬂ  ammation and a powerful acute 
phase response. Similar to other inﬂ  ammatory syn  dromes, 
GCA is a complex disorder with multiple pathogenic 
factors. An instigator initiating the inﬂ  am  matory process 
has not been identiﬁ  ed; however, over  whelming evidence 
has accumulated that abnormalities in innate and 
adaptive immunity play a critical role in the initiation and 
the perpetuation of the vasculitis.
Several unique factors of GCA have been informative 
in dissecting its immunopathogenesis. Th  e disease is 
characterized by a stringent tissue tropism; meaning that 
granulomatous wall inﬁ  ltrates typically appear in arteries 
of selected vascular beds. Th   is pathogenic feature 
strongly suggests that vessel-wall-speciﬁ   c factors drive 
GCA. Dendritic cells (DCs), similar to skin-residing 
Langerhans cells, have been implicated in providing 
initial signals that break the immune protection of 
arterial walls [2,3]. Vascular DCs are an endogenous cell 
population in the arteries. Th  ey  deﬁ  ne the immunological 
identity of blood vessels by expressing a vessel-speciﬁ  c 
proﬁ   le of pattern recognition receptors [4]. Activated 
vascular DCs recruit adaptive immune responses, sustain 
them in the vascular wall and shape their architecture 
and functional direction. Th  e nature of the adaptive 
immune response underlying the granulomatous reac-
tion is now well understood [5]. In essence, a selected 
population of T lymphocytes travels to the arterial lesion, 
undergoes local proliferation and activation and produces 
pro-inﬂ  ammatory cytokines regulating the functions of 
macrophages, vascular smooth muscle cells and endo-
thelial cells. T cells that accumulate in the granulo  matous 
lesions are non-random; identical T cells have been 
isolated from the right and left temporal artery of the 
same patient [6]. Th   e selectivity of the T cells involved in 
the disease process is highly suggestive for antigen as the 
ultimate driver of the inﬂ  ammation. Vasculitis T cells are 
functionally selected as well, and belong to either the T-
helper (Th  ) 1 or the Th  17 lineage [7]. In GCA patients, 
the two T-cell lineages are diﬀ   erentially responsive to 
cortico  steroid therapy and appear to be responsible for 
distinct aspects of the vasculitis process [8]. Th  e 
multiplicity of T-cell abnormalities suggests complexity 
in disease-driving signals, emphasizes the intricacy of the 
immune-mediated damage to the blood vessel and 
encourages multifaceted therapeutic approaches.
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Susceptibility for giant cell arteritis increases with 
chronological age, in parallel with age-related 
restructuring of the immune system and age-induced 
remodeling of the vascular wall. Immunosenescence 
results in shrinkage of the naïve T-cell pool, contraction 
of T-cell diversity, and impairment of innate immunity. 
Aging of immunocompetent cells forces the host to 
take alternative routes for protective immunity and 
confers risk for pathogenic immunity that causes 
chronic infl  ammatory tissue damage. Dwindling 
immunocompetence is particularly relevant as the 
aging host is forced to cope with an ever growing 
infectious load. Immunosenescence coincides 
with vascular aging during which the arterial wall 
undergoes dramatic structural changes and medium 
and large arteries lose their pliability and elasticity. On 
the molecular level, elastic fi  bers deteriorate and matrix 
proteins accumulate biochemical modifi  cations. Thus, 
the aging process impacts the two major biologic 
systems that liaise to promote giant cell arteritis; the 
immune system and the vessel wall niche.
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the T-cell biology of GCA, one critical disease factor has 
been less well examined. Th   e single strongest risk factor 
is age, with incidence steadily rising in the seventh to 
eighth decades of life [9,10]. Th   e disease essentially does 
not exist in individuals younger than 50 years of age. 
Progressive age could pose a risk to develop GCA 
through two major trajectories: age-related remodeling 
of the immune system, both the innate as well as the 
adaptive arm; and aging-imposed restructuring of the 
blood vessel wall. Takayasu’s arteritis, a granulomatous 
vasculitis of the aorta and its primary branches, aﬀ  ects 
individuals prior to age 40 years and thus unfolds on the 
background of a distinct immune system and a distinct 
vascular microenvironment. Understanding the impact 
of the aging process on the immune system and the 
vascular system are necessary components of a more 
comprehensive concept of GCA, its risk factors and its 
manageable pathogenic elements.
Age and the immune system
Th  e human immune system is designed to protect the 
host from infections, destroy malignant cells, regulate 
tissue healing and prevent immune responses to self. 
Over a lifetime, the immune system is challenged with a 
broad spectrum of infectious pathogens and responds 
with massive expansion of the cells required to destroy 
the invader and memorize the encounter for future 
protection. Th  e constant need to protect the host thus 
imposes enormous proliferative stress upon the bone-
marrow-derived cells that diﬀ   erentiate into immune-
competent cell types. With progressive age, production 
of new immune cells deteriorates. Th  is is particularly 
relevant for T lymphocytes as involution of the thymus 
essentially abrogates regeneration of T cells in middle 
age. Th   e question arises whether age-imposed changes in 
the pool of T lymphocytes increases the risk for GCA.
Th   e term immunosenescence is now used for a series of 
changes that are typically encountered in the immune 
system of the elderly (Table 1) [11]. First and foremost, 
the production of naïve T cells declines. In the thymus, 
bone-marrow-derived precursor cells develop into 
mature T cells and are checked for autoreactivity, at 
which time auto-reactive T cells are eliminated. T cells 
with low-aﬃ   nity for self antigens are released into the 
periphery where they form the pool of naïve T cells. 
Once T cells encounter their speciﬁ  c antigen, they enter a 
diﬀ   erentiation process and turn into memory and 
eﬀ  ector T cells. During middle age, the process of thymic 
T-cell production declines markedly and the naïve T-cell 
pool shrinks. Within the T-cell compartment, end-
diﬀ  erentiated memory and eﬀ  ector T cells replace naïve 
T cells. Chronic persistent infections place a particular 
strain on the immune system. Viral persistence, such as 
in cytomegalovirus infection, can drive chronic immune 
stimulation, which gradually exhausts the reserve of 
naïve T cells [12].
A prototypic change in end-diﬀ  erentiated T cells is the 
loss of the CD28 receptor from the cell surface. 
CD4+CD28- T cells were ﬁ  rst observed in patients with 
rheumatoid arthritis (RA) and their accumulation and 
clonality has given rise to the concept that RA patients 
have premature immune aging [13]. Other abnormalities 
typically encountered in the old are shifts in the 
distribution of CD4 and CD8 cells, a contraction in T-cell 
receptor diversity and loss of T-cell telomeres [14]. From 
studies testing vaccine responses in the elderly, it is 
known that only a fraction of over-65-year olds are 
capable of mounting protective immune responses and 
that the frequency of senescent CD8+CD28- T cells is an 
excellent predictor of non-responsiveness [15].
It is easy to understand that progressive age and 
contracting numbers of naïve T cells go hand in hand 
with declining immunity. It is more diﬃ   cult  to 
understand how the derangements of the T-cell system 
aﬀ  ect the ability to tolerate self. It is now clear that self-
tolerance is an active mechanism that depends on a well-
regulated immune system. Th  e strongest evidence that 
the aging immune system loses the capability to ﬁ  ne-tune 
immune responses and suppress those that would lead to 
self damage comes from the observation that the very old 
often have a state of chronic smoldering inﬂ  ammation 
[16]. Th   is chronic, low-grade inﬂ  ammation is sometimes 
called inﬂ  amm-aging. Cytokines, such as IL-6, TNF-α, 
and IL-1β, are suspected to have an important role in 
sustaining chronic inﬂ  ammation (Figure 1). Such cyto-
kines mainly derive from the innate immune system, 
suggesting that immunosenescence aﬀ  ects both the innate 
and adaptive immune systems. Continuous immune 
Table 1. The signature of immunosenescence
Adaptive immunity
  Decline of naïve T cells
  Enrichment of memory/eff  ector T cells
  Accumulation of CD8+CD28- T cells
  Less pronounced accumulation of CD4+CD28- T cells
  Contraction of diversity in the immune repertoire
Innate immunity
  Bias of the hematopoietic stem cell towards the myeloid lineage
  Maintained expression of pattern recognition receptors 
 (for  example,  TLR)
  Dendritic cell traffi   cking impaired
  Decreased dendritic cell response to TLR stimulation
Environmental stressors
  Increased infectious load
  Reactivation of persistent infections
TLR, Toll-like receptor.
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cytokines from other senescent cells, such as ﬁ  broblasts, 
have also been implicated as causative factors. Th  us,  age-
induced abnormalities in immune and non-immune cells 
may join forces to promote inﬂ   amm-aging (Figure 1). 
Parallel changes in the tissue microenvironment, leaving 
tissue-residing cells with a primed phenotype, could 
easily generate tissues that are more susceptible to the 
action of systemically produced pro-inﬂ  ammatory cyto-
kines. Th   e end result would be that enhanced synthesis of 
pro-inﬂ  ammatory mediators, such as IL-6, TNF-α, and 
IL-1β, exacerbates relatively benign tissue inﬂ  ammation 
and switches it into a destructive event.
In summary, immunosenescence describes a series of 
abnormalities in the innate and adaptive immune system 
(Table 1) that create a state of chronic inﬂ  ammation, 
impair anti-pathogen immune responses, increase 
susceptibility to malignancy and autoimmunity, decrease 
anti-vaccine responses and undermine wound healing. It 
is conceivable that such abnormalities also render 
individuals susceptible to vessel wall inﬂ  ammation.
Aging of T cells and dendritic cells
Th   e central cellular players in GCA are vessel-embedded 
DCs that sense danger signals and T cells that mount an 
adaptive immune response at the tissue site [17]. Both 
cell types are subject to aging, directly connecting 
immunosenescence and GCA susceptibility. T-cell aging 
is mostly determined by the inability of the thymus to 
replenish new T cells while maintaining memory T-cell 
responses and keeping check of chronic persistent 
infections [18]. Interestingly, aging of CD4 and CD8 
T cells proceeds at diﬀ  erent speeds [14]. CD8 T cells age 
faster, accumulate more CD28- cells and display a higher 
degree of clonality. Th  is may be a consequence of 
persistent viral infections, such as cytomegalovirus, 
which impose considerable stress upon CD8 T cells and 
induce restructuring of the immune system with 
progressive age. Little is known about the role of CD8 
T cells in GCA, other than the fact that they account for 
only a minor part of the vasculitic inﬁ  ltrate. Reports in 
the 1990s drew attention to the blood CD8 compartment 
in GCA [19,20].
A study performed in Denmark with 227 active, 
untreated GCA patients and 227 age- and gender-
matched controls revealed a signiﬁ  cant reduction in the 
CD8 population compared to controls (12% CD8 cells in 
patients versus 20% in age-matched controls). In several 
subsequent studies, decreased CD8 T-cell counts could 
not be conﬁ  rmed as a universal marker of GCA. Rather, 
Figure 1. Excessive production of pro-infl  ammatory cytokines in immune aging. The aging process results in an increase in basal cytokine 
production by macrophages, dendritic cells, endothelial cells and fi  broblasts. Whereas young cells require stimulation to secrete cytokines and thus are 
closely controlled, old cells release cytokines spontaneously. The elevation in spontaneous cytokine production in the absence of specifi  c stimulation 
results in a pro-infl  ammatory environment in which tissues are constantly ‘primed’ by cytokines. Chronic cytokine triggering may result in the 
generation of neoantigens and may contribute to the exhaustion of reserve pools supplying T cells and B cells. There is a corresponding decline in the 
ability of the immune system to mount a robust response as chronic cytokine exposure may alter the rheostat of cellular responsiveness.
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ratio in both patients and controls correlated closely with 
the number of clonal T-cell populations [21,22].
CD4 T cells, the major component of the GCA wall 
lesions, age slower, but essentially undergo similar changes 
as CD8 T cells with progressive age [14]. Detailed studies 
have shown that the aging process in CD4 cells is signiﬁ  -
cantly accelerated in RA, an autoimmune syndrome with 
chronic inﬂ   ammation of the synovial membrane and 
more rapid atherosclerosis. RA has emerged as a model 
system to study the interrelationship between chronic 
inﬂ   ammation and immune aging. Molecular defects 
described in RA patients may provide helpful insights 
into how the immune system ages overall and which 
particular pathways are relevant in the setting of chronic 
inﬂ   ammation. In RA patients, CD4 T-cell immuno-
senescence has been molecularly linked to a defect in 
repairing damaged DNA. Th  is defect involves the telo-
meric ends as well as non-telomeric genomic DNA. 
T  cells from RA patients fail to properly upregulate 
telomerase and thus are much less eﬃ   cient in protecting 
and repairing telomeres [23]. Also, T cells from RA 
patients have impaired upregulation of  ataxia 
telangiectasia mutated (ATM), a kinase critically relevant 
in recognizing double-strand breaks of non-telomeric 
DNA [16,24]. ATM has been implicated in participating 
in maintaining genomic integrity of the telomeric ends as 
well. In T cells from RA patients, damaged DNA 
accumulates and DNA repair mechanisms are blunted. 
Forced overexpression of ATM restores the ability to 
repair fragmented DNA and extends the life span of RA 
T cells. RA T cells sense that they fail to ﬁ  x DNA damage 
and chronically activate cell internal stress pathways 
[24,25]. It is currently unknown how these molecular 
networks are regulated in patients who have GCA. 
However, systemic inﬂ  ammation may undermine DNA 
damage recognition and repair, and therefore accelerate 
aging of the T-cell compartment. Recognizing the role of 
the DNA repair machinery in determining immuno-
senescence provides access to possible interventions to 
counteract the aging process in the immune system 
(Table 2). T cells orchestrate immune responses, both 
protective as well as harmful, by releasing cytokines. 
Recently, two cytokine-committed T-cell lineages have 
been implicated in GCA [7]. Th  1 cells produce IFN-γ, 
target macrophages and provide strong pro-inﬂ  ammatory 
function. In earlier studies, tissue IFN-γ levels have been 
correlated with the production of vascular endothelial 
growth factor and platelet-derived growth factor, 
molecules implicated in the neointimal response that 
leads to luminal stenosis [26,27]. Th   17 cells secrete IL-17, 
a cytokine that is known to regulate recruitment of 
neutrophils and provide protective immunity during 
early immune reactions, particularly indolent infections. 
Both Th   1 and Th   17 cells participate in GCA lesions. Th  17 
cells can be relatively easily suppressed with 
corticosteroids, whereas Th  1 cells are steroid-resistant 
and persist into the chronic phase of disease. Recent 
studies have reﬁ  ned the characterization of vasculitic T 
cells and have demonstrated that expression of the 
NOTCH1 receptor on T cells has an immediate role in 
the inﬂ  ammatory process [28].
Th   17 cells have also been implicated in atherosclerosis, 
a prototypic age-related syndrome in which mechanisms 
of immune and vascular aging interplay. Cells producing 
IFN-γ and IL-17 have been found in atherosclerotic 
plaques and are thought to create a pro-inﬂ  ammatory 
environment that causes abnormal function of vascular 
smooth muscle cells that eventually leads to plaque 
growth and instability [29]. It is possible that the aged 
immune system is biased towards the generation of Th  1 
cells, instead of relying more on Th  17  cells.
Whether DCs age at their own pace or in tandem with 
T cells, their major partner in the immune system, is yet 
unresolved. DC functions amenable to the aging process 
include their production, their homing to peripheral 
tissues, their responsiveness to ‘danger signals’, their 
migration from the periphery to central lymphoid organs 
and their direct interaction with T cells in the priming 
process. Studies of DC populations in GCA lesions have 
revealed that they are the critical antigen-presenting cells 
during early and late stages of disease [2]. Th   ey display an 
unusual phenotype in that they express the CCR7 
chemokine receptor. CCR7 expression on DCs is a sign of 
maturation and enables the DCs to follow a gradient of 
CCL19 and CCL21, two chemokines that direct the cells 
through lymph vessels into lymph nodes. In GCA lesions, 
DCs themselves produce high amounts of CCL19 and 
CCL21, triggering local trapping of the cells and 
preventing them from leaving the inﬂ  ammatory tissue 
niche [30].
Two studies in the human system and several studies in 
murine systems have approached the question of whether 
Table 2. Molecules involved in premature immune aging
Telomerase
 Insuffi   cient repair of telomeric ends in old T cells
Ataxia telangiectasia mutated
  Blunted repair of DNA double-strand breaks in old T cells
DNA-dependent protein kinase catalytic subunit (DNA-PKcs)
  Excessive activation of the DNA repair machinery with triggering of 
  cellular stress pathways in old T cells
Reactive oxygen species
  Impaired cellular detoxifi  cation of reactive oxygen species, accumulation 
  of oxidized lipids and proteins, modifi  cation of signaling proteins and 
 membranes
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immune-competence. In an inﬂ  uenza vaccine response 
study, Toll-like receptor (TLR) function of human DCs 
was assessed among 104 subjects. Older individuals were 
found to have DCs with lower TNF-α and IFN-α pro  duc-
tion in response to TLR stimulation compared to younger 
subjects. Older individuals also had higher intracellular 
cytokine levels in the absence of TLR triggering com-
pared to young [31]. In the murine model, young and old 
marrow-derived DCs were compared, and it has been 
shown that in vivo DC migration and CCR7 signal 
transduction are defective in aged DCs compared to their 
younger counterparts. Th  ough the migratory defect 
could be overcome by increasing the numbers of DCs, 
the defect in CD8 T-cell priming persisted [32]. Th  e 
ﬁ  ndings of these studies support the idea that DC aging 
impairs functional activity and that they may contribute 
to the observed inﬂ  amm-aging seen in the elderly. Other 
studies in both human and mice have shown that DCs, 
particularly plasmacytoid DCs, are susceptible to the 
aging process and this occurs both via decrease in 
population size and TLR function [33-36]. A molecular 
proﬁ   le of the age-related changes in T-cell and DC 
function that renders individuals susceptible to GCA or 
is caused by the inﬂ  ammatory activity in GCA has yet to 
be deﬁ  ned.
Vascular aging as a risk factor for giant cell arteritis
GCA displays a stringent tissue tropism for certain 
vascular territories. Such tissue tropism may result from 
selective availability of disease-relevant antigens. Alterna-
tively, vessel wall cell populations may contribute to 
disease initiation and the composition of the vessel wall 
may not be homogeneous through the vascular tree. 
Studies performed over the past 5 years have lent strong 
support for the second alternative. Speciﬁ  cally, a popu-
lation of immune-sensing cells, vascular DCs, have been 
identiﬁ  ed in the walls of medium and large arteries [17]. 
A population of vascular DCs is positioned at the media-
adventitia border of the human aorta and carotids, as 
well as subclavian, mesenteric, iliac and temporal 
arteries. Such vascular DCs provide immunosurveillance 
functions by sensing pathogen-derived molecular 
patterns (PAMPs). Th  ey utilize a spectrum of TLRs for 
this sensing function [4]. Remarkably, studies of normal 
human arteries from distinct vascular beds have shown 
that the TLR proﬁ  le in each arterial territory is vessel-
speciﬁ  c and unique [4]. Th   us, human arteries contribute 
to monitoring immune danger and they do so in a very 
selective way. Granulomatous lesions contain highly 
activated DCs, which have been implicated in promoting 
activation of vasculitic T cells [2]. Atherosclerotic 
plaques, another type of vascular lesion, are also 
populated by DCs, which shape the inﬂ  ammatory milieu 
and activate T cells [37]. Whether such lesional DCs 
derive directly from the wall-residing DC population or 
whether they are recruited from the blood stream is 
currently not known.
Vascular DCs have been implicated in initiating and 
sustaining mural inﬂ   ammation. Signals received by 
vascular DCs determine the microarchitecture of the 
evolving vascular inﬂ  ammation [38] and DCs are indis-
pensable for the recruitment and the guidance of T cells 
that enter the vessel wall [3]. Studies in human artery 
severe combined immunodeﬁ   ciency (SCID) mouse 
chimeras have demonstrated that each artery displays a 
selective sensing function and that each artery interacts 
with T cells in a vessel-speciﬁ  c pattern. In essence, at 
least part of the tissue tropism for GCA results from 
vessel-speciﬁ  c immune functions. Immune-sensing func-
tions of blood vessels may well be subject to age-related 
changes. It is not yet fully understood how the number, 
distribution, mobility and responsiveness to danger 
signals changes in vascular DCs as the host ages. 
However, substantial changes in the wall structure make 
it almost inevitable that vascular DCs in an 80-year old 
function distinctly from those in a 20-year old.
Functionality of the TLR-based sensing machinery in 
human dendritic cells is deﬁ   nitely susceptible to age-
related changes. Both myeloid and plasmacytoid DCs 
have been shown to be less responsive to TLR stimulation 
in older individuals [32]. While a decline in TLR 
responsiveness may suggest less pro-inﬂ  ammatory func-
tions deriving from ‘old’ DCs, such ‘old’ DCs would also 
loose anti-inﬂ  ammatory functions. Tolerogenicity of DCs 
is equally dependent on proper sensing functions. 
Deteriora  tion of tolerogenecity with advancing age would 
thus turn tolerogenic DCs into immune stimulator DCs 
(Figure 2). Th   e relative abundance of systemically distri-
buted pro-inﬂ   ammatory cytokines (for example, IL-6, 
TNF-α, IL-1) may indeed alter DC behavior and bias DCs 
towards a diﬀ  erent maturation program. It is well estab-
lished that older individuals fail to generate protective 
immune responses with similar eﬃ   ciency  as  younger 
counterparts [15,39]. While declining T-cell immunity 
has a central role in immunosenescence, DCs remain the 
major partners for T cells and are equally important in 
initiating and sustaining immune responses. Functional 
consequences for vascular DCs when chronically exposed 
to a milieu of inﬂ  ammation need to be explored.
Age-induced changes in blood vessel structure and 
function are not limited to wall-embedded immune-
competent DCs. From macroscopic and microscopic 
studies, it has long been known that the medial layer is 
prone to age-related degeneration [40,41] (Figure 3). 
Vascular smooth muscle cells decrease in number and 
function. Th   e media becomes thinner and deposition of 
calcium is not unusual. Overall, the arterial wall can 
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several layers. Elasticity of the arteries, mediated by the 
elastic ﬁ  bers and membranes integrated into the media, 
deteriorates, clinically recognized as increased stiﬀ  ness 
[42]. Th   e underlying mechanism relates to the fracture of 
elastic membranes and the ﬁ  zzing of elastic ﬁ  bers [43]. 
As life progresses, matrix proteins responsible for the 
facilitation of cell-cell interactions and the transmission 
of forces throughout the wall structure are biochemically 
modiﬁ   ed; changing structural features and transmural 
traﬃ     cking patterns for cells and molecules. Matrix 
proteins also serve as reservoirs for molecules released 
from wall-residing cells that promote communication 
between diﬀ  erent layers. In essence, the tissue niche of 
the vessel wall is profoundly altered by the aging process. 
Biochemical changes associated with vascular aging may 
actually be accelerated by inﬂ  ammatory damage of wall 
structures. In particular, vasculitis typically leads to 
fragmentation of elastic membranes and destruction of 
cell-protective matrix layers.
One of the molecular pathways implicated in molecular 
aging relates to oxidative stress, a process incriminated in 
aging overall [44]. As humans age, protective mechanisms 
detoxifying oxygen radicals are impaired. As a 
consequence, reactive oxygen species are more plentiful 
in the aged host. Such highly reactive oxygen species, 
derivatives of metabolic processes in the cell, are able to 
induce multiple biochemical modiﬁ  cations of proteins as 
well as membrane-integrated lipids. Aging of the aorta is 
associated with accumulation of advanced glycation end-
products and Alcian-blue positive mucin within the 
medial layer [41]. Glycation end-products have so far not 
been reported in medium-sized arteries, such as the 
temporal artery. Finally, endothelial cells are subject to 
aging. As prototypic vascular components, they not only 
line the macrolumen of medium and large arteries, but 
also form the microvascular vasa vasorum tree. Many of 
the immune recognition processes involved in GCA are 
located in the adventitia and the adventitia-adjacent 
media [45]. Th  is is the neighborhood dominated by the 
Figure 2. Aging of dendritic cells. Aging aff  ects both of the major functions of dendritic cells (DCs); stimulation and amplifi  cation of immunity 
and induction of peripheral tolerance. DCs are responsible for initiating and directing the immune response to antigens and play an integral role in 
the prevention of autoimmunity and unrestrained infl  ammation. Aged DCs are unable to effi   ciently prime and recruit T cells, migrate to peripheral 
lymph structures or maintain tolerance to self. They become trapped in peripheral tissues, perpetuating the immune response and can cause 
unresolved smoldering infl  ammation and subsequent tissue damage.
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vasorum tree has been identiﬁ  ed as an early abnormality 
in atherosclerotic disease [46]. Vasa vasora provide the 
entrance for inﬂ  ammatory cells in GCA lesions. Whether 
they have additional immunoregulatory functions in the 
early and late steps of the vasculitis is currently unknown. 
Insuﬃ   cient regeneration of endothelial layers by endo-
thelial precursor cells has been suspected as an important 
disease mechanism in multiple vascular patho  lo  gies. 
Organ-speciﬁ   c precursor cell populations decline with 
advancing age. Here, the aging process would have 
profound consequences for vessel wall integrity and 
function.
Conclusion
Progressive age, the strongest of all risk factors for GCA, 
impacts the two major elements that interact to cause 
vascular inﬂ  ammation; the innate and adaptive arms of 
the immune system and the unique microenvironment of 
the vessel wall. Clinically, immune aging is characterized 
by the loss of protective immunity and the occurrence of 
host-injurious inﬂ  ammation. Failure to protect the host 
results from the decline of immune cell regeneration. As 
a consequence, the elderly accumulate an increasing load 
of pathogens. Cells that survive in the aging immune 
system are less well controlled, spontaneously release 
cytokines and have altered threshold settings in response 
to immune stimuli. GCA is a disease of uncontrolled DC 
and T-cell activation in a tissue site that is ordinarily 
inaccessible for immune responses. As the host ages, the 
tissue site itself undergoes numerous structural changes, 
summarized as vascular aging. Th   is process brings with it 
changes in elastic ﬁ  bers, matrix proteins and remodeling 
of the medial and intimal layer, aﬀ  ecting cellular traﬃ   c, 
turnover and survival. An attractive hypothesis is that the 
infectious load of the aging host triggers activation of 
vascular DCs that can no longer protect the structurally 
altered vascular wall, giving rise to tissue-injurious 
inﬂ  ammation. Studies are needed to precisely deﬁ  ne how 
the aging process aﬀ  ects GCA-susceptible blood vessels 
and how vascular DCs change functionally and molecu-
larly as the host ages.
Figure 3. Age-related changes in vessel wall structure that enhance susceptibility to vasculitis. The vessel wall is prone to age-related 
changes that accumulate over a lifetime. Vascular stiff  ening results from biochemical changes of the cellular and extracellular components 
comprising the wall. Aged vessels typically lose elasticity and pliability. Elastic fi  bers/membranes show fatigue and fracture and matrix proteins 
accumulate biochemical modifi  cations. Cell numbers and cell mobility through the wall layers change. The overall eff  ect is a thinning of the medial 
layer, luminal widening and expansion of the intimal layer. Calcium deposition in the wall occurs frequently and may indicate foci of tissue injury. 
The ‘old’ artery provides a distinct microenvironment that potentially increases the risk for the homing and the persistence of pro-infl  ammatory 
immune cells and supplies a novel spectrum of neoantigens.
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Page 7 of 9Recent work has identiﬁ  ed at least two lineages of pro-
inﬂ  ammatory T cells contributing to GCA; Th   1 and Th  17 
cells. It is currently unknown whether the process of 
immunosenescence aﬀ  ects  Th  1 and Th  17 cells in a 
lineage-speciﬁ  c way or whether both T-cell types age in 
parallel. Th  e molecular details of T-cell aging in GCA 
remain to be elucidated. In GCA patients, Th   1 and Th  17 
cells diﬀ  er in therapeutic responsiveness and participa-
tion in early and chronic disease. Evidence suggests that 
the two lineages respond to distinct instigators. A 
combination of pathogen-derived and tissue-indigenous 
danger signals may result in the chronic granulomatous 
inﬂ   ammation that characterizes GCA. Th  erapeutic 
approaches for GCA patients need to be tailored to the 
special needs of the aging host. Immunosuppression 
needs to be restricted to avoid further weakening of 
immunocompetence. DCs originate from the bone 
marrow and the development of DC-target therapies will 
require a much better understanding of their life cycle. 
Enhancing immune cell regeneration could help in 
clearing chronic infections. Prevention of vascular aging 
is a long-drawn process that should begin during middle 
age. Given similarities in the inﬂ  ammatory process that 
typiﬁ   es atherosclerosis and GCA, it is possible that 
managing standard vascular risk factors could function 
as adjuvant therapy in the treatment of large vessel 
vasculitis.
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